Abcam, ab141673, U-37883A, ATP-sensitive K+ channel blocker

Size: 5mg
MW 382 Da, Purity >98%. ATP-sensitive potassium (KATP) channel blocker. Shows greater selectivity at KATP than at voltage-dependent and vascular inward rectifier K+ channels in smooth muscle cells. Active *in vivo* and *in vitro*.
Key facts
CAS number:57568-80-6,
Purity:>98%,
Molecular weight:382 Da,
Molecular formula:C21H36ClN3O,
PubChem:64392,
Nature:Synthetic,
Solubility:Soluble in water to 10 mM,
Biochemical name:PNU 37883 hydrochloride,
Biological description:ATP-sensitive potassium (KATP) channel blocker. Shows greater selectivity at KATP than at voltage-dependent and vascular inward rectifier K+ channels in smooth muscle cells. Active *in vivo* and *in vitro*.,
Canonical smiles:C1CCC(CC1)N=C(NC23CC4CC(C2)CC(C4)C3)N5CCOCC5.Cl,
InChi:InChI=1S/C21H35N3O.ClH/c1-2-4-19(5-3-1)22-20(24-6-8-25-9-7-24)23-21-13-16-10-17(14-21)12-18(11-16)15-21;/h16-19H,1-15H2,(H,22,23);1H,
InChiKey:FZALCKUJYZCDOX-UHFFFAOYSA-N,
IUPAC Name:N-(1-adamantyl)-N'-cyclohexylmorpholine-4-carboximidamide;hydrochloride

Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions-Ambient, Appropriate long-term storage conditions-Ambient, Storage information-The product can be stored for up to 12 months

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CYP2D6 also known as cytochrome P450 2D6 is a critical enzyme in the cytochrome P450 superfamily. It possesses a molecular mass of approximately 55 kDa. CYP2D6 is primarily expressed in the liver and to a lesser extent in the brain. As a monooxygenase it catalyzes the oxidation of organic substances including the metabolism of many xenobiotics and drugs. Its activity varies greatly among individuals due to genetic polymorphisms making it an important target for pharmacogenomic studies.
Biological function summary
Enzymes related to drug metabolism perform essential roles in the detoxification of foreign chemicals. CYP2D6 is notably part of the microsomal enzyme complex in the liver. It facilitates the transformation of lipophilic compounds into more water-soluble metabolites rendering them easier for the body to excrete. This enzyme affects the bioavailability and efficacy of many medications such as antidepressants antipsychotics and beta-blockers. Its role is integral in the activation of certain prodrugs converting them into their active pharmacological forms.
Pathways
CYP2D6 functions significantly in drug metabolism and clearance pathways. It takes part in the Phase I metabolism pathway where it initiates the oxidation of drugs setting the stage for further modifications. It interacts closely with other CYP enzymes like CYP3A4 which sometimes share substrates and inhibitors affecting their metabolic activities. CYP2D6's interaction with these pathways emphasizes its involvement in the intricate network of enzyme-mediated drug handling in the body.
Alterations in CYP2D6 activity relate to variations in drug metabolism leading to treatment challenges. For instance poor metabolizers may have increased risks of side effects or therapeutic failures in drugs like codeine which relies on CYP2D6 for activation. Additionally abnormal CYP2D6 activity associates with certain psychiatric disorders where specific drugs require precise metabolic conversion. The interaction between CYP2D6 and other proteins such as CYP3A4 further complicates its role in pharmacotherapy and its impact on individual responses to drugs.